MTCR — Metacrine Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
Metacrine: Up as NASH treatment gets FDA fast track tag
Brief: Metacrine Initiates Phase 2a Combination Trial Of MET409 With Empagliflozin In Patients With Type 2 Diabetes And NASH
Metacrine: Jumps on positive liver treatment study
Brief: Metacrine, Inc. Reports Positive Results From Phase 1 Trial Of Met642
Brief: Metacrine Reports Business Updates And Third Quarter 2020 Financial Results
U.S. RESEARCH ROUNDUP-Apple, Marsh & Mclennan, Travelers Companies
Brief: Metacrine To Present New Data From MET409 Program In NASH At AASLD's The Liver Meeting Digital Experience
Brief: New Enterprise Associates 16 Lp Reports 11.8% Stake Iny Metacrine Inc As Of Sept. 22
Metacrine: Rises at open in market debut
Brief: Metacrine Inc Shares Open 10.7% Above IPO Price In Debut On Nasdaq
NASDAQ RESUMED AT 11:31 AM
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:00 AM
Brief: Metacrine Says IPO OF 6.54 Mln Common Shares Priced At $13.00 per Share
Brief: Metacrine Offers 6.5 Million Shares In IPO
Brief: Metacrine Presents Positive Met409 Phase 1B Clinical Data In Nash Patients At The Digital International Liver Congress 2020